<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03597087</url>
  </required_header>
  <id_info>
    <org_study_id>SeoulNUH_2018_TURBT</org_study_id>
    <nct_id>NCT03597087</nct_id>
  </id_info>
  <brief_title>The Difference of Two Year Recurrence Rate According to Anesthetic Method During Transurethral Resection of Bladder Mass in Patients With Non-muscle Invasive Bladder Cancer: Prospective, Randomized, Clinical Phase II Study</brief_title>
  <official_title>The Difference of Two Year Recurrence Rate According to Anesthetic Method During Transurethral Resection of Bladder Mass in Patients With Non-muscle Invasive Bladder Cancer: Prospective, Randomized, Clinical Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators compare the recurrence rate difference between two years after
      transurethral resection of the bladder tumor according to the method of anesthesia.
      Anesthetic methods are general anesthesia and spinal anesthesia. Assessment of recurrence is
      assessed by bladder endoscopy, CT, and pathological examination of surgical specimens.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Research Background Most of the bladder cancer (approximately 85%) has histologic
           features of urothelial carcinoma. Approximately 75% of the patients initially diagnosed
           as non-invasive bladder cancer (stage I, CIS) or submucosal stage T1 -muscle invasive
           bladder cancer - NMIBC). However, it has been reported that about 60% to 70% of patients
           experience recurrence and 20% to 30% of relapsed cancers require radical cystectomy or
           chemotherapy It is known to progress to high-grade or high grade cancer.

           There are studies that involve surgical factors such as volatile anesthetics, narcotic
           analgesics, anti-body temperature, blood transfusion, and cancer recurrence. Minimizing
           the use of volatile anesthetics and narcotic analgesics reduces spinal anesthesia before
           and after surgery, It has been reported that there is a correlation with maintenance of
           immune cell function

        2. Research hypothesis and purpose The aim of this study was to evaluate the recurrence
           rate, recurrence - free survival rate, and recurrence - free survival rate of non -
           muscle invasive bladder carcinoma in patients undergoing bladder resection.

        3. Research Method

             -  Preoperative screening: Physical examination, Blood test, CT urography, Urine
                analysis, Urine culture, Urine cytology, Cystoscopy. Enforced

             -  Randomization on the day before surgery: 289 patients were randomly assigned to a
                spinal anesthesia group and a general anesthesia group 1: 1.

      Urine analysis, urine culture, urine cytology, and cystoscopy were performed every 3 months
      up to 2 years postoperatively. CT urography performed once a year

        -  Follow-up procedure: Follow-up procedure according to bladder cancer standard.

           4. Observation items, clinical examination items and observational examination methods

        -  Screening: CT urography, Urine analysis, Urine culture, Urine cytology, Cystoscopy.
           Observe

        -  Follow up: Urine analysis, Urine culture, Urine cytology, Cystoscopy every 3 months
           after the operation, CT urography every year
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 19, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>After randomization, they were divided into two parallel groups 289 patients were randomly assigned to a spinal anesthesia group and a general anesthesia group 1: 1.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Using a web site, and creating a randomized list at Sealedenvalop.com. Patients are randomly assigned to receive an anesthetic consent, and no masking is performed.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>2-year recurrence-free survival rate</measure>
    <time_frame>Follow up every 3 months until 2 years after surgery</time_frame>
    <description>The criteria for recurrence-free survival and recurrence of bladder cancer for 2 years postoperatively are based on pathological histology. If the recurrence is suspected in the radiological examination but pathological histological examination is difficult, the reference is based on the day of the imaging examination suspected of recurrence.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>2-year progression-free survival</measure>
    <time_frame>Follow up every 3 months until 2 years after surgery</time_frame>
    <description>The progression-free survival rate and progression rate of bladder cancer for 2 years postoperatively include both T stage and tumor grade progression.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">289</enrollment>
  <condition>Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>General anesthesia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group of general anesthesia before transurethral resection of the bladder tumor anesthesia: propopol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Spinal anesthesia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group of spinal anesthesia before transurethral resection of the bladder tumor anesthesia: bupibacaine</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Anesthesia before transurethral resection of the bladder tumor</intervention_name>
    <description>General anaesthesia or general anesthesia (see spelling differences) is a medically induced coma with loss of protective reflexes, resulting from the administration of one or more general anaesthetic agents.
Spinal anaesthesia is a form of regional anaesthesia involving the injection of a local anaesthetic into the subarachnoid space, generally through a fine needle</description>
    <arm_group_label>General anesthesia</arm_group_label>
    <arm_group_label>Spinal anesthesia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anesthesia</intervention_name>
    <description>General anaesthesia : propopol
Spinal anaesthesia : bupibacaine</description>
    <arm_group_label>General anesthesia</arm_group_label>
    <arm_group_label>Spinal anesthesia</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 18 years old or older

          2. Patients with suspected Ta / T1 non-muscle invasive bladder cancer

          3. Patients who were not previously treated with other cancers

          4. Normal range creatinine, AST, ALT patients

          5. Patients with both spinal anesthesia and general anesthesia

        Exclusion Criteria:

          1. Patients with urinary tract carcinoma not invading the renal pelvis, ureter or urethra

          2. Patients with cancer other than bladder cancer or a history of treatment

          3. Patients with clinical evidence of muscle-invasive bladder cancer

          4. Patients taking immunosuppressive drugs and immunosuppressive drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jin Tae Kim, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Professor, Department of Anesthesiology, Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ja Hyeon Ku, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Professor, Department of Urology, Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hyeong Dong Yuk, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical fellow, Department of Urology, Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Song Hee Kim, Bacheolor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Researcher, Department of Urology, Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jae Hyun Jung, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical fellow, Department of Urology, Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jung Hoon Lee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical fellow, Department of Urology, Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hyeong Dong Yuk, MD</last_name>
    <phone>+82-2-2072-1968</phone>
    <email>hinayuk@naver.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Song Hee Kim, Bacheolo</last_name>
    <phone>+82-2-2072-1968</phone>
    <email>songheekim0506@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <results_reference>
    <citation>Herr HW, Faulkner JR, Grossman HB, Natale RB, deVere White R, Sarosdy MF, Crawford ED. Surgical factors influence bladder cancer outcomes: a cooperative group report. J Clin Oncol. 2004 Jul 15;22(14):2781-9. Epub 2004 Jun 15.</citation>
    <PMID>15199091</PMID>
  </results_reference>
  <results_reference>
    <citation>Christodouleas JP, Baumann BC, He J, Hwang WT, Tucker KN, Bekelman JE, Tangen CM, Lerner SP, Guzzo TJ, Malkowicz SB, Herr H. Optimizing bladder cancer locoregional failure risk stratification after radical cystectomy using SWOG 8710. Cancer. 2014 Apr 15;120(8):1272-80. doi: 10.1002/cncr.28544. Epub 2014 Jan 3. Erratum in: Cancer. 2015 Jan 1;121(1):162. Herr, Harry [added].</citation>
    <PMID>24390799</PMID>
  </results_reference>
  <results_reference>
    <citation>Witjes JA, Compérat E, Cowan NC, De Santis M, Gakis G, Lebret T, Ribal MJ, Van der Heijden AG, Sherif A; European Association of Urology. EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. Eur Urol. 2014 Apr;65(4):778-92. doi: 10.1016/j.eururo.2013.11.046. Epub 2013 Dec 12.</citation>
    <PMID>24373477</PMID>
  </results_reference>
  <results_reference>
    <citation>Pollack A, Zagars GK, Cole CJ, Dinney CP, Swanson DA, Grossman HB. The relationship of local control to distant metastasis in muscle invasive bladder cancer. J Urol. 1995 Dec;154(6):2059-63; discussion 2063-4.</citation>
    <PMID>7500458</PMID>
  </results_reference>
  <results_reference>
    <citation>Jensen JB, Ulhøi BP, Jensen KM. Extended versus limited lymph node dissection in radical cystectomy: impact on recurrence pattern and survival. Int J Urol. 2012 Jan;19(1):39-47. doi: 10.1111/j.1442-2042.2011.02887.x. Epub 2011 Nov 3.</citation>
    <PMID>22050425</PMID>
  </results_reference>
  <results_reference>
    <citation>Zaghloul MS, Awwad HK, Akoush HH, Omar S, Soliman O, el Attar I. Postoperative radiotherapy of carcinoma in bilharzial bladder: improved disease free survival through improving local control. Int J Radiat Oncol Biol Phys. 1992;23(3):511-7.</citation>
    <PMID>1612951</PMID>
  </results_reference>
  <results_reference>
    <citation>Lawton CA, Michalski J, El-Naqa I, Buyyounouski MK, Lee WR, Menard C, O'Meara E, Rosenthal SA, Ritter M, Seider M. RTOG GU Radiation oncology specialists reach consensus on pelvic lymph node volumes for high-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2009 Jun 1;74(2):383-7. doi: 10.1016/j.ijrobp.2008.08.002. Epub 2008 Oct 22.</citation>
    <PMID>18947938</PMID>
  </results_reference>
  <results_reference>
    <citation>Baumann BC, Guzzo TJ, He J, Keefe SM, Tucker K, Bekelman JE, Hwang WT, Vaughn DJ, Malkowicz SB, Christodouleas JP. A novel risk stratification to predict local-regional failures in urothelial carcinoma of the bladder after radical cystectomy. Int J Radiat Oncol Biol Phys. 2013 Jan 1;85(1):81-8. doi: 10.1016/j.ijrobp.2012.03.007. Epub 2012 Apr 28.</citation>
    <PMID>22543204</PMID>
  </results_reference>
  <results_reference>
    <citation>Baumann BC, Guzzo TJ, He J, Vaughn DJ, Keefe SM, Vapiwala N, Deville C, Bekelman JE, Tucker K, Hwang WT, Malkowicz SB, Christodouleas JP. Bladder cancer patterns of pelvic failure: implications for adjuvant radiation therapy. Int J Radiat Oncol Biol Phys. 2013 Feb 1;85(2):363-9. doi: 10.1016/j.ijrobp.2012.03.061. Epub 2012 May 30.</citation>
    <PMID>22658217</PMID>
  </results_reference>
  <results_reference>
    <citation>Ku JH, Kim M, Jeong CW, Kwak C, Kim HH. Risk prediction models of locoregional failure after radical cystectomy for urothelial carcinoma: external validation in a cohort of korean patients. Int J Radiat Oncol Biol Phys. 2014 Aug 1;89(5):1032-1037. doi: 10.1016/j.ijrobp.2014.04.049. Epub 2014 Jul 8.</citation>
    <PMID>25035206</PMID>
  </results_reference>
  <results_reference>
    <citation>Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015 Mar 1;136(5):E359-86. doi: 10.1002/ijc.29210. Epub 2014 Oct 9.</citation>
    <PMID>25220842</PMID>
  </results_reference>
  <results_reference>
    <citation>Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015 Mar;65(2):87-108. doi: 10.3322/caac.21262. Epub 2015 Feb 4.</citation>
    <PMID>25651787</PMID>
  </results_reference>
  <results_reference>
    <citation>Babjuk M, Burger M, Compérat E, Palou J, Rouprêt M, van Rhijn B, Shariat S, Sylvester R, Zigeuner R, Gontero P, Mostafid H. Reply to Harry Herr's Letter to the Editor re: Marko Babjuk, Andreas Böhle, Maximilian Burger, et al. EAU Guidelines on Non-muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. Eur Urol 2017;71:447-61. Eur Urol. 2017 Jun;71(6):e173-e174. doi: 10.1016/j.eururo.2016.11.029. Epub 2016 Dec 7.</citation>
    <PMID>27939074</PMID>
  </results_reference>
  <results_reference>
    <citation>Burger M, Catto JW, Dalbagni G, Grossman HB, Herr H, Karakiewicz P, Kassouf W, Kiemeney LA, La Vecchia C, Shariat S, Lotan Y. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol. 2013 Feb;63(2):234-41. doi: 10.1016/j.eururo.2012.07.033. Epub 2012 Jul 25. Review.</citation>
    <PMID>22877502</PMID>
  </results_reference>
  <results_reference>
    <citation>Kamat AM, Witjes JA, Brausi M, Soloway M, Lamm D, Persad R, Buckley R, Böhle A, Colombel M, Palou J. Defining and treating the spectrum of intermediate risk nonmuscle invasive bladder cancer. J Urol. 2014 Aug;192(2):305-15. doi: 10.1016/j.juro.2014.02.2573. Epub 2014 Mar 25. Review.</citation>
    <PMID>24681333</PMID>
  </results_reference>
  <results_reference>
    <citation>Hall MC, Chang SS, Dalbagni G, Pruthi RS, Seigne JD, Skinner EC, Wolf JS Jr, Schellhammer PF. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol. 2007 Dec;178(6):2314-30. Review.</citation>
    <PMID>17993339</PMID>
  </results_reference>
  <results_reference>
    <citation>Morales A, Eidinger D, Bruce AW. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol. 1976 Aug;116(2):180-3.</citation>
    <PMID>820877</PMID>
  </results_reference>
  <results_reference>
    <citation>Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001 Feb 17;357(9255):539-45. Review.</citation>
    <PMID>11229684</PMID>
  </results_reference>
  <results_reference>
    <citation>Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010 Mar 19;140(6):883-99. doi: 10.1016/j.cell.2010.01.025. Review.</citation>
    <PMID>20303878</PMID>
  </results_reference>
  <results_reference>
    <citation>Kim HS, Ku JH. Systemic Inflammatory Response Based on Neutrophil-to-Lymphocyte Ratio as a Prognostic Marker in Bladder Cancer. Dis Markers. 2016;2016:8345286. doi: 10.1155/2016/8345286. Epub 2016 Jan 5. Review.</citation>
    <PMID>26880857</PMID>
  </results_reference>
  <results_reference>
    <citation>Crumley AB, McMillan DC, McKernan M, Going JJ, Shearer CJ, Stuart RC. An elevated C-reactive protein concentration, prior to surgery, predicts poor cancer-specific survival in patients undergoing resection for gastro-oesophageal cancer. Br J Cancer. 2006 Jun 5;94(11):1568-71.</citation>
    <PMID>16685271</PMID>
  </results_reference>
  <results_reference>
    <citation>Dutta S, Crumley AB, Fullarton GM, Horgan PG, McMillan DC. Comparison of the prognostic value of tumour and patient related factors in patients undergoing potentially curative resection of gastric cancer. Am J Surg. 2012 Sep;204(3):294-9. doi: 10.1016/j.amjsurg.2011.10.015. Epub 2012 Mar 22.</citation>
    <PMID>22444831</PMID>
  </results_reference>
  <results_reference>
    <citation>Kweon TD, Lee KY. Spinal anesthesia is associated with lower recurrence rates after resection of non-muscle invasive bladder cancer. Transl Androl Urol. 2018 Apr;7(2):283-286. doi: 10.21037/tau.2018.03.13.</citation>
    <PMID>29733090</PMID>
  </results_reference>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>July 2, 2018</study_first_submitted>
  <study_first_submitted_qc>July 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 24, 2018</study_first_posted>
  <last_update_submitted>July 13, 2018</last_update_submitted>
  <last_update_submitted_qc>July 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Ja Hyeon Ku</investigator_full_name>
    <investigator_title>Professor, MD., PHD.</investigator_title>
  </responsible_party>
  <keyword>Anesthesia, Bladder cancer, Recurrence rate, Transurethral resection of bladder mass</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

